Sector News

Goodbye pill, hello science: Pfizer debuts redesigned logo with double helix

January 10, 2021
Life sciences

Pfizer’s got a new blue. Two new blues in fact, with the company’s rebrand and new logo design. Gone is the staid blue oval pill background, replaced by a two-tone blue double helix spiral.

It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.

The new logo signals Pfizer’s “shift from commerce to science. We’ve unlocked the pill form to reveal the core of what we do,” Pfizer explains on its website.

Along with the redesign, Pfizer debuted two new video ads—one explaining the new logo and another that continues its “Science Will Win” campaign, begun in April. The second video features modern-day and historical images of scientists with bold letter proclamations and complementary voiceover statements, such as, “We believe science can cure every human disease—and we’re going all in.”

“Our new identity reflects the dignity of Pfizer’s history and captures the innovative spirit and science focus alive in the company today,” Sally Susman, executive VP and chief corporate affairs officer, said on the new Pfizer website.

CEO Albert Bourla added, “Pfizer is no longer in the business of just treating diseases—we’re curing and preventing them.”

The new logo is a result of 18 months of work, a Pfizer spokesperson said, in an email. That includes a pause on the creative work for several months beginning in March “as the company became laser-focused on the development of a COVID-19 vaccine.”

The process included surveying patients and doctors globally, as well as narrowing 200 designs down to four before selecting the eventual winner, according to a report in The Wall Street Journal.

The rebrand comes as Pfizer rides a reputation wave of good news, begun after it and partner BioNTech first announced positive COVID-19 vaccine data in November. Reports of the vaccine’s 95% effectiveness rate boosted Pfizer’s image with more than 48% of Americans who heard about it, agreeing it gave them a more positive view of the drugmaker.

by Beth Snyder Bulik

Source: fiercepharma.com

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach